Colon Cancer Stem Cells Fueled by Immune Cells

The aggressive properties of cancer stem cells are being fueled by a subset of immune cells directly targeting colon cancers rather than the immune system.

So finds a new study that is an international collaboration among researchers from the United States, China and Poland.

Aspirin Could Help Tackle Colon Cancer in Individuals Having a Specific Gene
People carrying high levels of a specific type of gene have a chance of reducing the risk of colon cancer by half with the intake of aspirin as per study released on Wednesday.

"If you want to control cancer stem cells through new therapies, then you need to understand what controls the cancer stem cells," says senior study author Weiping Zou, M.D., Ph.D., Charles B. de Nancrede Professor of surgery, immunology and biology at the University of Michigan Medical School.

Consider invasive Africanized honey bees. The worker honey bees are like the bulk majority of tumor cells while the queen bee is like the cancer stem cell. The queen bee can repopulate an entire colony but survives on royal jelly. If you remove the royal jelly, the queen bee dies and the entire colony of invasive Africanized honey bees can be removed. Th22-derived IL-22 is the royal jelly.

Th22 is a subset of a type of immune cell called T-cells. Typically, T-cells are the soldiers of the immune system, killing off tumor cells. In the case of colon cancer, the researchers found, Th22 acts as a tumor helper, actually supporting the cells in becoming able to renew - one of the hallmarks of cancer stem cells.

Key Steps Linking Dietary Fats and Colon Cancer Tumor Growth Found by Scientists
A new genetic evidence was shown by scientists that could strengthen the link between the role of dietary fats with colon cancer progression.

The researchers discovered that an epigenetic factor called DOT1L is regulated by IL-22, contributing to the cells developing stem cell properties. High levels of DOT1L in patient tumor samples were tied to shorter survival. The researchers suggest DOT1L may be a marker for colon cancer progression, and that this pathway could potentially be targeted in new colon cancer treatments.

The researchers are now looking at potential drugs that might target this process directly. No specific therapies are currently available.

Web Information on Colon Cancer too Complex, Do Not Address Key Concerns
Popular web information on colorectal cancer is too difficult for most lay people to read and doesn't address the appropriate risks to and concerns of patients.

Tumor immunology and immunotherapy has become a hot research topic recently. Science named it the breakthrough of the year in 2013. Zou''s group has been among the pioneers in understanding how the immune system plays a role in cancer.

The study was led by Ilona Kryczek, Yanwei Lin and Nisha Nagarsheth. Results appear online in the journal Immunity.

Source-Newswise